Quick Answer
Keros Therapeutics, Inc. reported Total Revenue of $244.06 million for fiscal year 2025.
Keros Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $244.06M | +6775.0% |
| 2024 | $3.55M | +2251.0% |
| 2023 | $151.0K | — |
| 2022 | $0.00 | -100.0% |
| 2021 | $20.10M | — |
| 2020 | $0.00 | -100.0% |
| 2019 | $10.00M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.26M | +3575.8% | -21.5% |
| June 30, 2025 | $18.17M | +49002.7% | -91.4% |
| March 31, 2025 | $211.25M | +254413.3% | +54344.8% |
| September 30, 2024 | $388.0K | +4750.0% | +948.6% |
| June 30, 2024 | $37.0K | — | -55.4% |
| March 31, 2024 | $83.0K | — | +937.5% |
| September 30, 2023 | $8.0K | — | — |
| June 30, 2023 | $0.00 | — | — |
- Keros Therapeutics, Inc. showed an increase of +6775.0% in Total Revenue compared to the prior fiscal year.
- Over the 2019–2025 period, Keros Therapeutics, Inc.’s total revenue has grown by 2340.6% (from $10.00 million to $244.06 million).
- The most recent figure is from Keros Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: